2. Search Result
Search Result
Results for "

Hepcidin inhibitor

" in MedChemExpress (MCE) Product Catalog:

23

Inhibitors & Agonists

1

Biochemical Assay Reagents

2

Peptides

5

Inhibitory Antibodies

2

Natural
Products

1

Isotope-Labeled Compounds

3

Oligonucleotides

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-13426
    Roxadustat
    Maximum Cited Publications
    59 Publications Verification

    FG-4592

    		 HIF/HIF Prolyl-Hydroxylase Ferroptosis Infection Cancer
    Roxadustat is an orally active hypoxia-inducible factor prolyl-hydroxylase (PHD) inhibitor (HIF-PHI) that promotes erythropoiesis through increasing endogenous erythropoietin, improving iron regulation, and reducing hepcidin .
    Roxadustat
  • HY-113066C
    Guanosine 5'-diphosphate sodium, 96% (HPLC)
    2 Publications Verification

    GDP sodium, Type I, 96% (HPLC)

    		 Hepcidin Potassium Channel Endogenous Metabolite Interleukin Related STAT Inflammation/Immunology Cancer
    Guanosine 5'-diphosphate (GDP) sodium, 96% (HPLC) is a nucleoside diphosphate that activates adenosine 5'-triphosphate-sensitive K + channel. Guanosine 5'-diphosphate sodium, 96% (HPLC) is an iron mobilizer, which forms a complex with hepcidin to inhibit the hepcidin-ferroportin (FPN) interaction and modulates the IL-6/stat-3 pathway. Guanosine 5'-diphosphate sodium, 96% (HPLC) ameliorates the Turpentine-induced anemia of inflammation (AI) in mice when combined with FeSO4. Guanosine 5'-diphosphate sodium, 96% (HPLC) can be used in the research of AI .
    Guanosine 5'-diphosphate sodium, 96% (HPLC)
  • HY-112220
    VIT-2763
    5+ Cited Publications

    		 Ferroportin Metabolic Disease
    VIT-2763, an oral ferroportin inhibitor, inhibits hepcidin binding to ferroportin and blocks iron efflux. VIT-2763 has the potential in the treatment of β-thalassemia .
    VIT-2763
  • HY-P99590A
    Sotatercept (mIgG2a)
    1 Publications Verification

    RAP-011

    		 TGF-β Receptor TGF-beta/Smad Cardiovascular Disease Metabolic Disease
    Sotatercept (mIgG2a) (RAP-011), the murine homolog of Sotatercept (ACE-011) (HY-P99590), is a soluble activin receptor type IIA (ActRIIA) ligand trap. Sotatercept (mIgG2a) inhibits the binding of activin A and other members of the TGF-β superfamily (such as Activin A/B, GDF11 and BMP9/10) to their receptors by combining and neutralizing them, thereby regulating cell proliferation and differentiation. Sotatercept (mIgG2a) mainly inhibits the SMAD2/3 signaling pathway, and can be used in various diseases such as chronic kidney disease. Sotatercept (mIgG2a) reduces the expression of erythropoietic hepcidin (ERFE), regulates iron metabolism, and promotes red blood cell production. Sotatercept (mIgG2a) has a dual effect of promoting bone formation (anabolic) and inhibiting bone resorption (catabolic) .
    Sotatercept (mIgG2a)
  • HY-113066
    Guanosine 5'-diphosphate

    GDP

    		 Hepcidin Potassium Channel Endogenous Metabolite Interleukin Related STAT Inflammation/Immunology Cancer
    Guanosine 5'-diphosphate (GDP) is a nucleoside diphosphate that activates adenosine 5'-triphosphate-sensitive K + channel. Guanosine 5'-diphosphate is an iron mobilizer, which forms a complex with hepcidin to inhibit the hepcidin-ferroportin (FPN) interaction and modulates the IL-6/stat-3 pathway. Guanosine 5'-diphosphate ameliorates the Turpentine-induced anemia of inflammation (AI) in mice when combined with FeSO4. Guanosine 5'-diphosphate can be used in the research of AI .
    Guanosine 5'-diphosphate
  • HY-145608
    Zilurgisertib

    INCB-000928; NBU-928

    		 TGF-β Receptor Cardiovascular Disease Cancer
    Zilurgisertib (INCB-000928; NBU-928) is a selective ALK2 inhibitor with an IC50 value of 15 nM. Zilurgisertib inhibits SMAD1/5 phosphorylation with an IC50 value of 63 nM. Zilurgisertib inhibits hepcidin production and improve anemia. Zilurgisertib can be used in melanoma research .
    Zilurgisertib
  • HY-13426S
    Roxadustat-d5

    		HIF/HIF Prolyl-Hydroxylase Ferroptosis Cancer
    Roxadustat-d5 is deuterium labeled Roxadustat. Roxadustat is an oral hypoxia-inducible factor prolyl-hydroxylase inhibitor (HIF-PHI) that promotes erythropoiesis through increasing endogenous erythropoietin, improving iron regulation, and reducing hepcidin .
    Roxadustat-d5
  • HY-107980
    DS28120313

    		Ferroportin Inflammation/Immunology
    DS28120313 (compound 32) is an orally hepcidin production inhibitor with an IC50 of 0.093 μM .
    DS28120313
  • HY-P11260
    MD5

    		Ser/Thr Protease Thrombin Metabolic Disease
    MD5 is a selective TMPRSS6 mimetic peptide inhibitor with an IC50 for recombinant human TMPRSS6 protein of 22 nM and a Ki of 3.4 nM. MD5 exhibits the significantly reduced inhibitory effect on Matriptase, with an IC50 of 352 nM and a Ki of 99.2 nM. MD5 exhibits good target specificity and only has a weak inhibitory effect on thrombin (Thrombin), with Ki of 120 nM. MD5 demonstrates good initial drugability and can be used for the study of iron overload diseases (such as hereditary hemochromatosis, β-thalassemia) .
    MD5
  • HY-125288
    DS42450411

    		Ferroportin Metabolic Disease
    DS42450411 is an orally active hepcidin production inhibitor with an IC50 of 32 nM. DS42450411 in an acute inflammatory mouse model induced by IL-6, DS42450411 significantly reduces serum hepcidin levels. DS42450411 can be used for studying iron homeostasis .
    DS42450411
  • HY-P4370
    Hepcidin-20 (human)

    		Bacterial Fungal Infection
    Hepcidin-20 (human) is a histidine-containing, cysteine-rich, β-sheet structured peptide. Hepcidin-20 (human) shows antifungal activity. Hepcidin-20 (human) inhibits biofilm formation and bacterial cell metabolism of polysaccharide intercellular adhesin (PIA)-positive and PIA-negative strains .
    Hepcidin-20 (human)
  • HY-177641A
    Lexaptepid Pegol sodium

    NOX-H94 sodium

    		 Hepcidin Others
    Lexaptepid Pegol sodium is a pegylated structured L-oligoribonucleotide. It binds and inhibits hepcidin.
    Lexaptepid Pegol sodium
  • HY-177641
    Lexaptepid Pegol

    NOX-H94

    		 Hepcidin Others
    Lexaptepid Pegol is a pegylated structured L-oligoribonucleotide. It binds and inhibits hepcidin.
    Lexaptepid Pegol
  • HY-145965
    Ferroportin-IN-1

    		Ferroportin Metabolic Disease
    Ferroportin-IN-1 is a ferroportin inhibitor extracted from patent WO2020123850A1 compound 23. Ferroportin-IN-1 can be used for the research of diseases caused by a lack of hepcidin or iron metabolism disorders .
    Ferroportin-IN-1
  • HY-13426R
    Roxadustat (Standard)

    FG-4592 (Standard)

    		 Reference Standards HIF/HIF Prolyl-Hydroxylase Ferroptosis Cancer
    Roxadustat (Standard) is the analytical standard of Roxadustat. This product is intended for research and analytical applications. Roxadustat is an orally active hypoxia-inducible factor (HIF) prolyl-hydroxylase (PHD) inhibitor (HIF-PHI) that promotes erythropoiesis through increasing endogenous erythropoietin, improving iron regulation, and reducing hepcidin .
    Roxadustat (Standard)
  • HY-W064657
    Momelotinib dihydrochloride

    		JAK Others
    Momelotinib (dihydrochloride) is a JAK1/JAK2 inhibitor that also antagonizes ACVR1, leading to downregulation of Hepcidin expression and increased availability of iron for erythropoiesis. Momelotinib (dihydrochloride) can reduce transfusion burden and spleen enlargement caused by myelofibrosis, showing potential value in research and application within the field of myelofibrosis .
    Momelotinib dihydrochloride
  • HY-123878
    DS79182026

    		Hepcidin Inflammation/Immunology
    DS79182026 is an inhibitor of hepcidin production. DS79182026 exhibits hepcidin lowering ability in IL-6-induced acute inflammatory mouse model .
    DS79182026
  • HY-149833
    ERRγ inverse agonist 2

    		Estrogen Receptor/ERR Infection Metabolic Disease
    ERRγ inverse agonist 2 (compound 19) is a potent and selective ERRγ inverse agonist with a Kd value of 6.5 μM. ERRγ inverse agonist 2 inhibits the expression of hepcidin, fibrinogen and gluconeogenic genes. ERRγ inverse agonist 2 has antimicrobial, anti-coagulant and antidiabetic activities .
    ERRγ inverse agonist 2
  • HY-P991637
    REGN7999

    		Ser/Thr Protease Metabolic Disease
    REGN7999 is a monoclonal antibody that inhibits TMPRSS6. REGN7999 inhibits TMPRSS6 activity, preventing Hemojuvelin (HJV) lysis, thereby enhancing BMP6-HJV signaling and increasing serum hepcidin. REGN7999 ameliorates iron overload and impaired erythropoiesis in a β-thalassemia mouse model by inhibiting TMPRSS6 activity. REGN7999 is indicated for research in β-thalassemia .
    REGN7999
  • HY-107980R
    DS28120313 (Standard)

    		Hepcidin Ferroportin Reference Standards Inflammation/Immunology
    DS28120313 (Standard) is the analytical standard of DS28120313 (HY-107980). This product is intended for research and analytical applications. DS28120313 (compound 32) is an orally hepcidin production inhibitor with an IC50 of 0.093 μM .
    DS28120313 (Standard)
  • HY-P991855
    RKER-216

    		TGF-β Receptor Metabolic Disease
    RKER-216 is a human monoclonal IgG antibody inhibitor targeting ALK2 with a KD of 58.7 pM. RKER-216 reduces hepcidin transcription in Hep3B.RKER-216 competes with BMP ligands for binding to the extracellular domain of ALK2, thereby inhibiting BMP-SMAD signal. RKER-216 mobilizes tissue iron effectively in inflammatory conditions. RKER-216 improves microcytic anemia in a dose-dependent manner by inhibiting SMAD signaling to reduce hepcidin and promote iron absorption and utilization in vivo. RKER-216 can be used for research on anemia of inflammation .
    RKER-216
  • HY-P992451
    RLYB331

    KY1066

    		 Ser/Thr Protease Hepcidin Reactive Oxygen Species (ROS) Apoptosis Cardiovascular Disease
    RLYB331 (KY1066) is a is a monoclonal antibody targeting Matriptase-2 (TMPRSS6) . RLYB331 binds to the serine protease active site of matriptase-2, blocking protease activity to increase hepcidin expression. RLYB331 reduces iron overload, inhibits α-aggregates, reduces ROS, inhibits apoptosis, and enhances erythroid differentiation. RLYB331 ameliorates ineffective erythropoiesis in β-thalassemic mouse models. RLYB331 can be used for the research of β-thalassemia .
    RLYB331
  • HY-P991881
    KY1070

    		TGF-β Receptor Hepcidin Ferroportin Cardiovascular Disease
    KY1070 is a fully human anti-BMP6 antibody with a Kd of 0.00014 μM against the human BMP6. It exhibits high specificity for BMP6, showing no cross-reactivity with other members of the BMP family, and effectively inhibits BMP6-induced BMP receptor heterodimerization and hepcidin expression. KY1070 modulates Ferroportin expression on erythroid progenitor cells and accelerates erythropoiesis. In rodent anemia models, KY1070 reduces the required dose of erythropoietin (EPO) when used in combination with EPO and enhances the responsiveness of mice with chronic kidney disease (CKD)-associated anemia to EPO treatment. KY1070 is applicable for research on anemia of chronic disease [1] [2].
    KY1070

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: